8-K: Oragenics Submits Clinical Trial Protocol for Phase II Concussion Trial in New Zealand

Oragenics has submitted its clinical trial protocol to the Health and Disability Ethics Committee (HDEC) in New Zealand for its Phase II clinical trial of ONP-002 for mild traumatic brain injury (mTBI) or concussion.

Summary

• Oragenics, Inc. has announced the submission of its clinical trial protocol to the Health and Disability Ethics Committee (HDEC) in New Zealand.
• This submission is for a Phase II clinical trial evaluating ONP-002, a neurosteroid therapy, for the treatment of mild traumatic brain injury (mTBI) or concussion.
• The trial is expected to be conducted at Christchurch Hospital in New Zealand, a large teaching and research hospital.
• The hospital's Emergency Department treats over 83,000 patients annually.
• Patient enrollment is planned in both Australia and New Zealand.
• ONP-002 is designed for intranasal administration and has shown promising results in preclinical models by reducing inflammation, oxidative stress, and brain swelling.
• A Phase I clinical study demonstrated that the drug is safe and well-tolerated in healthy human volunteers.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical development and the potential to address an unmet medical need. However, the forward-looking statements and inherent risks in clinical trials temper the enthusiasm.

Positives

• The submission of the clinical trial protocol is a significant step in advancing ONP-002.
• ONP-002 targets an unmet medical need, as there is currently no pharmaceutical therapy available for treating concussion.
• The intranasal administration of ONP-002 offers a non-invasive route for drug delivery to the brain.
• Preclinical studies have shown promising results for ONP-002 in reducing inflammation, oxidative stress, and brain swelling.
• The Phase I study demonstrated the drug's safety and tolerability in humans.

Risks

• The forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• Regulatory feedback is pending and could impact the trial's progress.
• Patient enrollment is planned but not guaranteed.

Future Outlook

Oragenics expects to initiate patient enrollment in New Zealand and expand the study's geographic reach, pending approval from the HDEC.

Management Comments

• Janet Huffman, Interim Chief Executive Officer of Oragenics, stated that submitting the HDEC application is a pivotal step toward advancing ONP-002 and addressing the critical need for effective concussion treatments.
• Huffman also mentioned the plan to expand the global clinical footprint with patient enrollment in Australia and New Zealand.

Industry Context

The development of ONP-002 addresses a significant unmet need in the treatment of concussion, as no pharmaceutical therapy is currently available. This positions Oragenics as a potential first-mover in this space.

Comparison to Industry Standards

• Currently, there are no approved pharmaceutical therapies specifically for concussion, making ONP-002 a novel approach.
• Other companies are exploring various treatments for traumatic brain injury, but Oragenics' intranasal delivery method and neurosteroid approach differentiate it from many competitors.
• Comparisons to other companies are difficult due to the lack of directly comparable approved therapies.

Stakeholder Impact

• Positive impact on patients suffering from mild traumatic brain injury (mTBI) or concussion if the trial is successful.
• Potential positive impact on shareholders if ONP-002 progresses through clinical trials and receives regulatory approval.

Next Steps

• Await regulatory feedback from the HDEC.
• Initiate patient enrollment in New Zealand, pending approval.
• Expand the study's geographic reach to Australia.

Key Dates

Keywords

ONP-002, concussion, clinical trial, Oragenics, mTBI, HDEC, neurosteroid, intranasal, therapy